ArticleNPJ vaccines2025
Deletion of B125R increases protection induced by a genotype II African swine fever vaccine candidate.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- African swine fever virus genes vectored by simian adenoviruses do not protect against virulent genotype II virus challenge.Microbiology spectrum · 2026Article
- Deletion of the African swine fever virus E120R gene completely attenuates its virulence by enhancing host innate immunity and impairing virus release.Emerging microbes & infections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A modified live attenuated African swine fever genotype II virus, GΔDKE-CmutQ96R/K108D, with deletions of three genes, DP148R, EP153R, and K145R and expressing a mutated CD2v protein with a non-haemadsorbing phenotype, was further modified by first removing two reporter gene cassettes expressing fluorescent proteins. The B125R gene was then deleted and one reporter cassette was reinserted as a marker. Groups of pigs were immunised with this virus using a range of doses from 100 to 10,000 infectious particles. One pig immunised with the lowest dose reached a moderate severity humane endpoint. The other pigs showed mild or no clinical signs. Low levels of the virus used for immunisation were detected post-immunisation. After challenge with virulent virus, all pigs were protected, and few clinical signs were observed. Low levels of replication of the challenge virus were detected in seven from the twenty-three challenged pigs and no virus in the remaining pigs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.